Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

DOI: 10.1002/path.4934
Journal of Pathology, 2017, 243, 26-36.

#	Paper	IF	Citations
61	Perimenopausal management of ovarian endometriosis and associated cancer risk: When is medical or surgical treatment indicated?. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2018**, 51, 151-168	4.6	28
60	Clear cell carcinomas of the ovary and kidney: clarity through genomics. *Journal of Pathology*, **2018**, 244, 550-564	9.4	27
59	Origin of clear cell carcinoma: nature or nurture?. *Journal of Pathology*, **2018**, 244, 131-134	9.4	6
58	Novel CTCF mutations in Chinese patients with ovarian endometriosis. *Molecular Medicine Reports*, **2018**, 18, 1031-1036	2.9	4
57	When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy. *Frontiers in Oncology*, **2018**, 8, 654	5.3	13
56	Diseases of the Peritoneum. **2018**, 1-71		
55	Pathogenesis, Genetics, and Genomics of Non-High Grade Serous Ovarian Cancers. *Hematology/Oncology Clinics of North America*, **2018**, 32, 929-942	3.1	2
54	Distinct molecular pathways in ovarian endometrioid adenocarcinoma with concurrent endometriosis. *International Journal of Cancer*, **2018**, 143, 2505-2515	7.5	5
53	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. *F1000Research*, **2018**, 7, 189	3.6	3
52	The Endometriotic Tumor Microenvironment in Ovarian Cancer. *Cancers*, **2018**, 10,	6.6	24
51	Contemporary management of adnexa at the time of benign hysterectomy: a review of the literature. *Journal of Obstetrics and Gynaecology*, **2019**, 39, 896-902	1.3	2
50	Endometrial Carcinoma. **2019**, 455-513		1
49	Endometriosis and Endometriosis-Associated Tumors. **2019**, 405-426		
48	Ovarian Epithelial Carcinogenesis. **2019**, 121-139		1
47	Pathology of Endometrioid and Clear Cell Carcinoma of the Ovary. *Surgical Pathology Clinics*, **2019**, 12, 529-564	3.9	30
46	Diseases of the Peritoneum. **2019**, 771-840		2
45	Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. *Cancer Research*, **2019**, 79, 5536-5549	10.1	9

44	How many cell types form the epithelial lining of the human uterine tubes? Revision of the histological nomenclature of the human tubal epithelium. *Annals of Anatomy*, **2019**, 224, 73-80	2.9	10
43	Motile ciliogenesis and the mitotic prism. *Biology of the Cell*, **2019**, 111, 199-212	3.5	6
42	Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage. *Journal of Ovarian Research*, **2019**, 12, 30	5.5	9
41	p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. *American Journal of Surgical Pathology*, **2019**, 43, 1591-1599	6.7	19
40	Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. *EBioMedicine*, **2019**, 50, 203-210	8.8	25
39	Increased androgen receptor levels and signaling in ovarian cancer cells by VEPH1 associated with suppression of SMAD3 and AKT activation. *Journal of Steroid Biochemistry and Molecular Biology*, **2020**, 196, 105498	5.1	6
38	Use of Immunohistochemical Markers (HNF-1β, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. *International Journal of Gynecological Pathology*, **2020**, 39, 344-353	3.2	5
37	Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites. *American Journal of Human Genetics*, **2020**, 107, 622-635	11	5
36	Cells expressing PAX8 are the main source of homeostatic regeneration of adult mouse endometrial epithelium and give rise to serous endometrial carcinoma. *DMM Disease Models and Mechanisms*, **2020**, 13,	4.1	11
35	Pathology of clear cell carcinoma of the ovary: A basic view based on cultured cells and modern view from comprehensive approaches. *Pathology International*, **2020**, 70, 591-601	1.8	5
34	MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread. *Oncogene*, **2020**, 39, 4045-4060	9.2	7
33	Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. *Cancers*, **2020**, 12,	6.6	13
32	SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. *Annual Review of Pathology: Mechanisms of Disease*, **2020**, 15, 467-492	34	23
31	Association between endometriosis and gynecological cancers: a critical review of the literature. *Archives of Gynecology and Obstetrics*, **2020**, 301, 355-367	2.5	16
30	Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla-Site of Origin of Serous Carcinoma of the Ovary. *Cancers*, **2020**, 12,	6.6	4
29	Should All Endometriotic Cysts Be Removed?. *Advances in Medical Diagnosis, Treatment, and Care*, **2021**, 274-287	0.2	
28	Cysteine Metabolism in Cancer Progression and Therapy Resistance. **2021**, 155-191		
27	Does the "Devil" originate from the fallopian tubes?. *Seminars in Cancer Biology*, **2021**, 77, 56-66	12.7	4

26	Clinical and Pathological Significance of Cellular Atypia in Endometriosis. *Medicina (Lithuania)*, **2021**, 57,	3.1	
25	Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study. *Journal of Ovarian Research*, **2021**, 14, 63	5.5	1
24	Ovarian Cancer: Biomarkers and Targeted Therapy. *Biomedicines*, **2021**, 9,	4.8	4
23	STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. *Journal of Pathology: Clinical Research*, **2021**, 7, 548-555	5.3	2
22	A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer. *Frontiers in Oncology*, **2021**, 11, 668151	5.3	2
21	Exploiting epigenetic dependencies in ovarian cancer therapy. *International Journal of Cancer*, **2021**, 149, 1732-1743	7.5	0
20	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. *Acta Clinica Belgica*, **2021**, 1-13	1.8	1
19	Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening. *American Journal of Surgical Pathology*, **2021**, 45, 1452-1463	6.7	4
18	Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. *Journal of Cancer*, **2021**, 12, 2295-2316	4.5	2
17	Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer. *Biomedicines*, **2021**, 9,	4.8	1
16	Ovarian Carcinoma Associated with Endometriosis. **2018**, 47-64		
15	Unraveling endometriosis-associated ovarian carcinomas using integrative proteomics. *F1000Research*, **2018**, 7, 189	3.6	3
14	Dynamic changes in the urine proteome in two ovarian cancer rat models.		1
13	PAX8 expressing epithelial cells are a cancer-prone source of clonal cyclical regeneration of endometrial epithelium.		
12	Ovarian Cancer Risk Variants are Enriched in Histotype-Specific Enhancers that Disrupt Transcription Factor Binding Sites.		
11	The Evolution of Ovarian Carcinoma Subclassification.. *Cancers*, **2022**, 14,	6.6	5
10	Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis.. *Frontiers in Endocrinology*, **2022**, 13, 762589	5.7	0
9	Transsulfuration, minor player or crucial for cysteine homeostasis in cancer.. *Trends in Cell Biology*, **2022**,	18.3	4

8	A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes.. *Cell Reports Medicine*, **2022**, 3, 100542	18	5
7	A Systematic Review of Atypical Endometriosis-Associated Biomarkers.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	1
6	Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman StudyTM. *Current Oncology*, **2022**, 29, 3318-3340	2.8	
5	The proteome of clear cell ovarian carcinoma.		0
4	New insights of liquid biopsy in ovarian cancer. **2022**, 5, 001-011		0
3	Bovine and human endometrium-derived hydrogels support organoid culture from healthy and cancerous tissues. **2022**, 119,		0
2	Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression. **2022**, 11, 4009		1
1	Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development.		0